本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

MacroGenics Inc.

1.56
-0.0250-1.58%
成交量:51.24萬
成交額:81.01萬
市值:9,828.49萬
市盈率:-2.68
高:1.62
開:1.56
低:1.55
收:1.58
52周最高:5.10
52周最低:0.9897
股本:6,320.57萬
流通股本:5,166.65萬
量比:1.27
換手率:0.99%
股息:- -
股息率:- -
每股收益(TTM):-0.5792
每股收益(LYR):-1.0694
淨資產收益率:-60.25%
總資產收益率:-26.29%
市淨率:1.24
市盈率(LYR):-1.45

資料載入中...

公司資料

公司名字:
MacroGenics Inc.
交易所:
NASDAQ
成立時間:
2000
員工人數:
341
公司地址:
9704 Medical Center Drive,Rockville,Maryland,United States
郵編:
20850
電話:
傳真:
301 251 5321
簡介:
Macrogenics, Inc.於2000年8月14日在美國特拉華州註冊成立。該公司是一家臨床階段的生物製藥公司,專註於發現、開發、製造和商業化用於治療癌症的創新抗體療法。該公司通過其專有的一套下一代抗體技術平台,開發候選產品,並相信這個平台可以提高單克隆抗體和抗體衍生分子的性能。藉助疾病生物學和免疫介導機制的知識,該公司已確定這些候選產品或許能應對現有療法無法治療的特定疾病所帶來的挑戰。公司既開發了針對新癌症靶點的分化分子,又提升了已上市藥品的功效。

董事

名稱
職位
Eric Risser
Director, President and Chief Executive Officer
William K. Heiden
Chairman of the Board
David Stump
Independent Director
Edward Hurwitz
Independent Director
Federica O'Brien
Independent Director
Jay Siegel
Independent Director
Karen Jean Ferrante
Independent Director
Margaret A. Liu
Independent Director
Meenu Chhabra Karson
Independent Director
Scott T. Jackson
Independent Director

股東

名稱
職位
Eric Risser
Director, President and Chief Executive Officer
Ezio Bonvini
Senior Vice President, Research and Chief Scientific Officer
James Karrels
Senior Vice President, Chief Financial Officer and Corporate Secretary
Jeffrey Stuart Peters
Senior Vice President, General Counsel and Corporate Compliance Officer
Stephen L. Eck
Senior Vice President, Clinical Development and Chief Medical Officer
Thomas Spitznagel
Senior Vice President, Technical Operations
Beth Smith
Vice President, Controller, Treasurer and Principal Accounting Officer